Vor Bio
Healthcare & Life Sci
Company overview
Vor Bio develops therapies for autoimmune diseases, aiming to correct the underlying biology rather than just control symptoms. Its lead product, telitacicept, is a first-in-class BAFF/APRIL inhibitor designed to rebalance immunity and deliver consistent clinical benefit.
Telitacicept has 5 approvals in China across multiple autoimmune conditions, treating tens of thousands of patients there commercially. Jean-Paul Kress, MD serves as Chief Executive Officer and Chairman.
- Industry
- Healthcare & Life Sci
- Headquarters
- Boston, United States